Abstract
Drug repurposing, the use of established drugs in new, previously unrelated indications, offers many potential advantages, such as lower development costs and higher success probabilities in clinical trials, which is thought to be attractive especially for orphan indications. This analysis was conducted to assess the success of repurposed drugs (RD) in German HTA procedures and subsequent price negotiations based on AMNOG.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have